Italy, France, Germany, and the Netherlands, which are part of the COVID-19 Alliance (inclusive Vaccine Alliance, IVA), created to develop a vaccine for coronavirus infection, will pay AstraZeneca for the production of 300 million doses of € 750 million. Reuters reported this regarding a representative of the Italian Ministry of health. Thus, the cost of a single dose of the Oxford-developed vaccine, called AZD1222, will be € 2.5.
At the same time, Italy itself, explained the representative of the Ministry, will pay € 185 million for 75 million doses of the vaccine, that is, about € 2.47 per dose.
Earlier, the Italian Ministry of Health said that the COVID-19 vaccine would be distributed free of charge, with people belonging to risk groups being the first to receive it.
“The vaccine is the only way to solve the COVID-19 problem finally. For me, it will always be a global public good, the right of everyone, not the privilege of a few,” said Italian health Minister Roberto Speranza.
The IVA participants signed a contract with AstraZeneca, under which the vaccine can be provided to customers by the end of 2020, was announced on June 13. However, the amount of the contract was not disclosed at the time.
“The vaccine will be purchased at cost, but the exact price to be paid for a potential vaccine is not disclosed due to the Alliance’s negotiating position,” the Dutch government said on Saturday. This position was explained by the fact that until the last stage of creating the vaccine, likely, it will not be sent to mass production.
The AstraZeneca report noted that the cost of producing the vaccine would be covered by the governments of the IVA member countries.
AstraZeneca also said that AZD1222 was tested on 320 people, and during the tests, it was proved that patients well tolerate the vaccine. However, there may be short-term side effects, such as fever, headache, aching limbs, or symptoms of SARS. At the same time, the company assured that vaccination could not lead to infection with COVID-19. For the human immune system to learn to attack the disease-causing virus SARS-CoV-2, one treatment is enough.